Zoldonat injection market seen reaching $2.4 billion by 2030

The zoldonat injection market is projected to grow from $1.84 billion in 2026 to $2.4 billion by 2030, driven by rising osteoporosis cases, higher healthcare spending and broader use of intravenous bisphosphonate therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The market outlook points to sustained demand for bone health treatments as osteoporosis, cancer-related bone complications and aging populations increase worldwide. - Zoldonat injection sits in the broader shift toward intravenous therapies that manage bone loss and support oncology care. - The forecast suggests room for both branded and generic zoledronate products as access to specialty care expands.

What happened: - The Business Research Company released its Zoldonat Injection Market Report 2026, covering market size, trends and a global forecast through 2035. - The report says the zoldonat injection market will rise from $1.73 billion in 2025 to $1.84 billion in 2026. - The report projects the market will reach $2.4 billion by 2030. - The report puts the 2025-2026 growth rate at 6.6% and the 2026-2030 growth rate at 6.8%. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to grow the fastest during the forecast period.

The details: - Zoldonat injection contains zoledronic acid, a bisphosphonate that reduces bone resorption and helps regulate bone metabolism. - The product is administered intravenously. - The report links recent growth to higher rates of osteoporosis and other bone disorders. - The report also cites more cancer-related bone complications, an aging population, wider adoption of intravenous bisphosphonate therapies and expanding healthcare infrastructure. - Looking ahead, the report expects stronger demand for therapies that manage bone loss, more generic zoledronate products and increased need for oncology supportive care. - The report also points to better access to specialty healthcare services and more advanced injectable drug delivery systems. - Market trends highlighted in the report include newer bisphosphonate formulations, targeted approaches to bone metabolism management, broader use of hospital-based intravenous osteoporosis treatments, affordable generic formulations and efforts to improve adherence and access. - The report includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa in its regional analysis.

Between the lines: - The market is being pulled by two forces at once: more patients who need bone-loss treatment and more health systems able to deliver it. - Generic competition appears poised to widen treatment access, even as specialty and hospital-based care remain central to the category. - The report’s emphasis on adherence and accessibility suggests manufacturers and providers are trying to reduce barriers that can limit long-term osteoporosis treatment. - The release also includes a sample report link and a full report link: Download a free sample and View the full report.

What's next: - The report expects continued expansion through 2030 as demand for bone-loss therapies rises. - Growth may accelerate as healthcare spending increases and access to specialty treatment improves. - New product development in bisphosphonate formulations and injectable delivery could shape the next phase of competition. - The Business Research Company also highlighted updated 2026 report features including TAM analysis, company scoring matrices, Excel dashboards, market hotspots infographics and updated graphics and tables.